Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Intravenous administration of lidocaine perioperatively after laparotomy for peritonitis could be an interesting alternative by reducing the duration of postoperative ileus, the intensity of pain and the patient's hospital stay, as well as the cost of management in our context of lack of financial, technical and human resources, hence the present study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lidocaine group | Experimental | The group will receive 1.5 mg/kg lidocaine 2% bolus, followed by a continuous electric syringe dose of 1.5 mg/kg/hour intraoperatively, then 1.5 mg/kg/hour during the first 24 hours postoperatively |
|
| Saline group | Placebo Comparator | The control group will receive an equivalent volume of saline: the volume of saline to be administered will be obtained by considering the dose of lidocaine 2% that the patient would have received if he/she had been in the interventional group. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lidocaine intravenous | Drug | Perioperative lidocaine intravenous administration |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Resumption of transit | time to first gas and/or presence of bowel sounds | Up to 7 days during the postoperative period. From the date of randomization to the first postoperative gas and/or the presence of postoperative bowel sounds in the patient |
| Measure | Description | Time Frame |
|---|---|---|
| Analog visual scale | Average pain score, minimal value is 0, maximal value is 10 and higher score mean worse | Postoperative pain scores at 24 hours |
| Concentration of C-reactive protein | Average of C-reactive protein |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bertille KI, Doctor | Contact | +22670230257 | bertilleki@yahoo.fr | |
| Ismael GUIBLA, Doctor | Contact | +22676135113 | ismaelguibla@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Nazinigouba OUEDRAOGO, Professor | JOSEPH KI-ZERBO University | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| D010538 | Peritonitis |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
This will be a randomized, double-blind clinical trial conducted at University hospital Charles De Gaulle of Ouagadougou, comparing the results of intravenous administration of lidocaine perioperatively versus administration of saline
Not provided
Not provided
Not provided
| Serum saline intravenous |
| Drug |
Perioperative serum saline intravenous administration |
|
| Hours 24 postoperative |
| Hospitalisation | Number of days in hospital | Up to 30 days during the postoperative period. From the date of randomization to the patient's discharge from hospital or date of death |
| Postoperative mortality | Number of postoperative deaths | Up to 30 days during the postoperative period. From date of randomization to date of death |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D059413 | Intraabdominal Infections |
| D007239 | Infections |
| D010532 | Peritoneal Diseases |
| D004066 | Digestive System Diseases |